IONIS PHARMACEUTICALS INC (IONS)
IONIS PHARMACEUTICALS INC (IONS) from its SEC filings: 2025 revenue $943.7 million (+34% vs the year before), net margin -40%, free cash flow -$320.0 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $943.7 million |
| Revenue growth | +34% |
| Net income | -$381.4 million |
| Net margin | -40.4% |
| Free cash flow | -$320.0 million |
| Diluted EPS | $-2.38 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | -41% |
| Cash | $350.1 million |
| Long-term debt | $1.3 billion |
| Share count, 1 year | +4% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.